Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on April 24, 2025
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, …
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire
·
April 24, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and …
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8 …
Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
GlobeNewswire
·
April 24, 2025
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and …
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
GlobeNewswire
·
April 24, 2025
TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 24, 2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of €130 million and (ii) the debt …
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire
·
April 24, 2025
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Treace to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it …
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
GlobeNewswire
·
April 24, 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development …
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 24, 2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 …
Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance
GlobeNewswire
·
April 24, 2025
First Quarter Highlights† Reported revenue of $355.4 million, up 9.8% Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively GAAP operating margin of 11.5%, compared to 11.1% in prior year period Non-GAAP …
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society
GlobeNewswire
·
April 24, 2025
Fort Mill, S.C., April 24, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their …
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
GlobeNewswire
·
April 24, 2025
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological …
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
GlobeNewswire
·
April 24, 2025
► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la …
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
GlobeNewswire
·
April 24, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial …
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
GlobeNewswire
·
April 24, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 …
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
GlobeNewswire
·
April 24, 2025
Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the …
Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report
GlobeNewswire
·
April 24, 2025
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, …
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
GlobeNewswire
·
April 24, 2025
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease …